Back

Incidence of community acquired lower respiratory tract disease in Bristol, UK following the emergence of SARS-CoV-2: a prospective cohort study 2020-2024

Chatzilena, A.; Hyams, C.; Challen, R.; Begier, E.; Southern, J.; Lahuerta, M.; McGuinness, S.; Clout, M.; Campling, J.; Oliver, J.; Vyse, A.; Ellsbury, G.; Maskell, N.; Gessner, B.; Finn, A.; Danon, L.; The Avon CAP Research Group,

2025-03-17 respiratory medicine
10.1101/2025.03.17.25324087 medRxiv
Show abstract

Surveillance of acute lower respiratory tract disease (aLRTD) is fundamental for understanding population health burden and healthcare needs. COVID-19 altered the epidemiology of respiratory infections, but post-pandemic aLRTD incidence and severity remain underexplored in the UK. We conducted a prospective cohort study of adults ([≥]18 years) admitted to two Bristol hospitals (August 2020-July 2024) with symptoms or a diagnosis of pneumonia, non-pneumonic lower respiratory tract infection (NP-LRTI), or no evidence of LRTI. Of 457,112 hospitalizations, 44,792 (9.8%) were due to aLRTD: 48.2% pneumonia, 35.2% NP-LRTI, and 16.7% no LRTI. Incidence peaked in 2021-22 (14.4/1,000 person-years) due to COVID-19 before stabilizing around 13.6. SARS-CoV-2 pneumonia declined; non-COVID pneumonia remained stable. Mortality risk was lower for NP-LRTI (HR 0.32) and no LRTI (HR 0.43) compared to pneumonia. Older age and comorbidities increased mortality. Non-COVID infections persisted despite interventions, emphasizing the need for surveillance and vaccination in public health planning.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.